INDIANAPOLIS - Eli Lilly & Co. (NYSE: NYSE: ), a pharmaceutical giant with a market capitalization of more than $700 billion and an impressive gross profit margin of about 81%, has received approval from China's National. medical (TASE:) Product Administration (NMPA) for Kisunla™ (donanemab-azbt), marking it as the fourth major market approval after the United States, Japan, and Great Britain. Accordingly Investment Prof Data, Lilly maintains a good financial health score, positioning it strongly for this expansion. Kisunla is intended for the treatment of adults with early-onset Alzheimer's disease, including those with mild cognitive impairment (MCI) and those with mild dementia who have confirmed amyloid pathology.
In China, the prevalence of Alzheimer's disease is significant, affecting approximately 6% of the population over the age of 65, with projections suggesting an increase to 11% by 2050. The approval of Kisunla, which targets amyloid plaque formation in the brain, provides a new treatment option. Management of disease. With revenue growth of 27% over the past twelve months and strong earnings forecasts, Lilly appears well-positioned to capitalize on this market opportunity.
TRAILBLAZER-ALZ 2 Phase 3 clinical study demonstrates approval of NMPA. This study found that Kisunla significantly slowed the progression of Alzheimer's disease in participants, especially those with less advanced disease. Patients demonstrated a 35% slower decline in cognitive and daily function compared to placebo patients. Additionally, Kisunla demonstrated up to 84% reduction in amyloid plaques at 18 months, with 66% of patients achieving plaque clearance at one year.
Despite these promising results, Kisunla is associated with potential side effects, such as amyloid-related imaging abnormalities (ARIA), which can include transient brain swelling or bleeding, and infusion-related reactions. However, ARIA is often asymptomatic and can usually be monitored and managed with an MRI scan.
Kisunla is given intravenously every four weeks, with a dosing regimen that may allow treatment to be discontinued after amyloid plaques are removed, potentially reducing treatment costs and frequency of infusions. .
The approval of Kisunla in China is based on a press release statement from Eli Lilly and Company and offers a new way to address the challenges of Alzheimer's disease in a population with increasing prevalence of the condition. For investors seeking deeper insight into Lilly's growth potential and comprehensive analysis, Investment Prof Offers exclusive access to 15+ additional pro-tips and a detailed pro research report, helping you make informed investment decisions in the pharmaceutical sector.
In other recent news, pharmaceutical giant Eli Lilly and Innovent Biologics announced an agreement giving Innovent exclusive rights to import, market, distribute and promote Lilly's cancer drug Japirca® in mainland China. The partnership aims to address unmet clinical needs in the treatment of hematologic cancers and increase patient access to innovative treatments. In another development, Eli Lilly's weight loss drug Manjaro is gaining preference among UK customers over Novo Nordisk's (NYSE: ) Wegovi, marking a significant shift in the UK weight loss drug market. Bernstein analysts recognize Eli Lilly as a major player in the growing global obesity drug market, projected to reach $95 billion by 2030, and maintain an outperform rating on the company. Furthermore, according to the European Medicines Agency's Committee for Medicinal Products for Human Use, Eli Lilly's drug Omwoh is close to approval by the European Union for the treatment of Crohn's disease. These are just a few recent developments in Eli Lilly's journey.
This article was produced with support from AI and was reviewed by an editor. See our T&C for more information.